Mark Guinan
Director/Board Member chez UPHEALTH, INC.
Fortune : 14 M $ au 31/03/2024
Profil
Actuellement, Mark J. Guinan occupe le poste de directeur financier et vice-président exécutif chez Quest Diagnostics, Inc. M. Guinan est également membre du conseil d'administration de Myovant Sciences Ltd, Q Squared Solutions Holdings Ltd et Roivant Sciences, Inc. Auparavant, il a occupé les postes de directeur financier et de vice-président principal chez Hill-Rom Holdings, Inc, de vice-président des finances du Global Pharmaceutical Group, de directeur des achats chez Johnson & Johnson et de directeur chez Procter & Gamble Co. Mark J. Guinan a obtenu un diplôme de premier cycle à l'université de Notre Dame et un MBA à l'Olin Business School.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
08/03/2023 | 106 038 ( 0,10% ) | 14 M $ | 31/03/2024 | |
UPHEALTH INC
0,86% | 31/01/2024 | 160 606 ( 0,86% ) | 167 030 $ | 31/03/2024 |
Postes actifs de Mark Guinan
Sociétés | Poste | Début |
---|---|---|
UPHEALTH, INC. | Director/Board Member | 05/12/2022 |
Q Squared Solutions Holdings Ltd.
Q Squared Solutions Holdings Ltd. Medical/Nursing ServicesHealth Services Part of IQVIA Holdings, Inc., Q Squared Solutions Holdings Ltd. is a British company that provides health services. The private company is based in Reading, UK. | Director/Board Member | - |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Director/Board Member | - |
Anciens postes connus de Mark Guinan
Sociétés | Poste | Fin |
---|---|---|
MYOVANT SCIENCES LTD. | Director/Board Member | 10/03/2023 |
QUEST DIAGNOSTICS INCORPORATED | Director of Finance/CFO | 11/07/2022 |
HILL-ROM HOLDINGS, INC. | Director of Finance/CFO | 19/07/2013 |
JOHNSON & JOHNSON | Corporate Officer/Principal | 01/01/2010 |
PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Formation de Mark Guinan
University of Notre Dame | Undergraduate Degree |
Olin Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
JOHNSON & JOHNSON | Health Technology |
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
QUEST DIAGNOSTICS INCORPORATED | Health Services |
UPHEALTH, INC. | Health Services |
Entreprise privées | 5 |
---|---|
Hill-Rom Holdings, Inc.
Hill-Rom Holdings, Inc. Hospital/Nursing ManagementHealth Services Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL. | Health Services |
Global Pharmaceutical Group | |
Myovant Sciences Ltd.
Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Q Squared Solutions Holdings Ltd.
Q Squared Solutions Holdings Ltd. Medical/Nursing ServicesHealth Services Part of IQVIA Holdings, Inc., Q Squared Solutions Holdings Ltd. is a British company that provides health services. The private company is based in Reading, UK. | Health Services |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |